Related Experiment Video

Updated: Jun 4, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K

KMT2A degradation is observed in decitabine-responsive acute lymphoblastic leukemia cells

Luisa Brock1, Lina Benzien1, Sandra Lange1

  • 1Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Germany.

Molecular Oncology
|January 4, 2025
PubMed

Insights

Decitabine, a hypomethylating agent, degrades DNA methyltransferase 1 (DNMT1) and also reduces KMT2A protein in acute lymphoblastic leukemia (ALL) cells. This KMT2A reduction is key to decitabine's anti-leukemic effects in ALL.

Area of Science:

  • Epigenetics
  • Cancer Biology
  • Hematology

Background:

  • Hypermethylation of tumor suppressor genes is characteristic of leukemia.
  • Decitabine is a hypomethylating agent that targets DNA (cytosine-5)-methyltransferase 1 (DNMT1).
  • Structural similarities between DNMT1 and KMT2A suggest decitabine may affect KMT2A.

Purpose of the Study:

  • To investigate the effect of decitabine on KMT2A expression in acute lymphoblastic leukemia (ALL).
  • To determine if KMT2A degradation is necessary for decitabine's anti-leukemic activity.
  • To explore decitabine's potential as a therapeutic agent for ALL.

Main Methods:

  • Treatment of ALL cell lines and xenograft models with decitabine.
  • Analysis of DNMT1 and KMT2A expression levels (mRNA and protein).
  • Cell cycle analysis and gene expression profiling of primary ALL samples.

Main Results:

  • Decitabine treatment led to increased DNMT1 and KMT2A expression initially, followed by DNMT1 degradation.
  • KMT2A protein levels were reduced in cells where DNMT1 was degraded.
  • Reduced KMT2A protein correlated with biological effects, including cell cycle arrest (G2/G1) and differential gene expression patterns.
  • Decitabine showed anti-leukemic activity in adult ALL cells, potentially synergizing with menin inhibition.

Conclusions:

  • Decitabine induces anti-leukemic activity in ALL cells through KMT2A degradation.
  • KMT2A status (wild-type vs. rearranged) influences cellular response to decitabine.
  • Decitabine warrants consideration as a potential therapeutic option for ALL.
Keywords:
DNMT1KMT2Aacute leukemiadecitabinemeninrevumenib

More Related Videos

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

8.1K
Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

8.2K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K